The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Osilodrostat (Isturisa®) has been rejected for use in the treatment of endogenous Cushing’s syndrome in adults. The manufacturer failed to make a submission for this indication. In considering the product license, it would be expected that this medicine would be prescribed and monitored by a specialist.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.